In fact, in 46 patients with metastatic or nonresectable ccRCC treated with sunitinib, low plasma IL6 at baseline was associated with significant response to sunitinib and improved PFS, suggesting that upregulation of plasma IL-6 might represent an important mechanism of resistance [137]. The gene discussed is IL6; the disease is nonpapillary renal cell carcinoma.